May 09, 2022 4:30pm EDT Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
Apr 29, 2022 5:00pm EDT Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 08, 2022 1:00pm EDT Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
Apr 05, 2022 7:00am EDT Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 30, 2022 4:05pm EDT Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC
Mar 03, 2022 7:00am EST Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
Feb 28, 2022 4:35pm EST Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
Jan 06, 2022 7:00am EST Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Jan 05, 2022 4:30pm EST Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
Dec 27, 2021 7:00am EST Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
